In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains

Journal of Chemotherapy

Volumn 20, Issue 4, 2008, Pages 441-444

  Huelves, Lorena ^a   Del Prado, G ^a   Gracia, M ^a   Rodriguez Cerrato V ^a   Ponte, C ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Mice; Miltefosine; Peritonitis; Pneumococcus; Sepsis

Indexed keywords

AMOXICILLIN; MILTEFOSINE; PENICILLIN G;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONITIS; SEPSIS; STREPTOCOCCUS PNEUMONIAE; SURVIVAL RATE;

EID: 52249120114     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.4.441     Document Type: Article

References (14)

1. Ruiter GA, Verheij M, Zerp SF, van Blitterswijk WJ. Alkyllysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int J Radiat Oncol Biol Phys 2001; 49(2): 415-419.
2. Santa-Rita RM, Henriques-Pons A, Barbosa HS, de Castro SL. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J Antimicrob Chemother 2004; 54(4): 704-710.
3. Croft SL, Snowdon D, Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 1996; 38(6): 1041-1047.
4. Nakayama H, Loiseau PM, Bories C, Torres de Ortiz S, Schinini A, Serna E, et al. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniasis. Antimicrob Agents Chemother 2005; 49(12): 4950-4956.
5. Widmer F, Wright LC, Obando D, Hanke R, Ganendren R, Ellis DH, et al. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. Antimicrob Agents Chemother 2006; 50(2): 414-421.
6. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fisher C, et al. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 1999; 341(24): 1795-1800.
7. Rosenow C, Ryan P, Weiser JN, Johnson S, Fontan P, Ortqvist A, et al. Contribution of novel choline-binding proteins to adherence, colonization and immunogenicity of Streptococcus pneumoniae. Mol Microbiol 1997;25(5):819-829.
8. Llull D, Rivas L, García F. In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci. Antimicrob Agents Chemother 2007; 51(5): 1844-1848.
9. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standards. 7th ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2006.
10. O'Reilly T, Cleeland R, Squires EL. Evaluation of antimicrobials in experimental animal infections. In: Lorian V, ed. Antibiotics in laboratory medicine. 4th edition. Baltimore, MD: Williams & Wilkins, 1996: 604-765.
11. Huelves L, Sevillano D, Martínez-Marín C, López-Casla MT, Gracia M, Alou L, et al; Spanish Pneumococcal Infection Study Network (G03/103). Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones. Int J Antimicrob Agents. 2006; 27(4): 294-299.
12. Breiser A, Kim DJ, Fleer EA, Damenz W, Drube A, Berger M, et al. Distribution and metabolism of hexadecylphosphocholine in mice. Lipids 1987; 22(11): 925-926.
13. Unger C, Fleer E, Damenz W, Hilgard P, Nagel G, Eibl U. Hexadecylphosphocholine: determination of serum concentrations in rats. J Lipid Mediat 1991; 3(1): 71-78.
14. Marschner N, Kotting J, Eibl H, Unger C. Distribution of hexadecylphosphocholine and octadecyl-methyl-glycero-3-phosphocholine in rat tissues during steady-state treatment. Cancer Chemother Pharmacol 1992; 31(1): 18-22.